#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


Text=Disrupted modulation of thalamus activation and thalamocortical connectivity during dual task performance in schizophrenia Despite considerable evidence showing thalamus anatomy and connectivity abnormalities in schizophrenia, how these abnormalities are reflected in thalamus function during cognition is relatively understudied.
1-1	0-9	Disrupted	_
1-2	10-20	modulation	_
1-3	21-23	of	_
1-4	24-32	thalamus	_
1-5	33-43	activation	_
1-6	44-47	and	_
1-7	48-63	thalamocortical	_
1-8	64-76	connectivity	_
1-9	77-83	during	_
1-10	84-88	dual	_
1-11	89-93	task	_
1-12	94-105	performance	_
1-13	106-108	in	_
1-14	109-122	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-15	123-130	Despite	_
1-16	131-143	considerable	_
1-17	144-152	evidence	_
1-18	153-160	showing	_
1-19	161-169	thalamus	_
1-20	170-177	anatomy	_
1-21	178-181	and	_
1-22	182-194	connectivity	_
1-23	195-208	abnormalities	_
1-24	209-211	in	_
1-25	212-225	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
1-26	226-227	,	_
1-27	228-231	how	_
1-28	232-237	these	_
1-29	238-251	abnormalities	_
1-30	252-255	are	_
1-31	256-265	reflected	_
1-32	266-268	in	_
1-33	269-277	thalamus	_
1-34	278-286	function	_
1-35	287-293	during	_
1-36	294-303	cognition	_
1-37	304-306	is	_
1-38	307-317	relatively	_
1-39	318-330	understudied	_
1-40	331-332	.	_

Text=Modulation of thalamic connectivity with the prefrontal cortex (PFC) is required for higher-order cognitive processes, which are often impaired in schizophrenia.
2-1	333-343	Modulation	_
2-2	344-346	of	_
2-3	347-355	thalamic	_
2-4	356-368	connectivity	_
2-5	369-373	with	_
2-6	374-377	the	_
2-7	378-388	prefrontal	_
2-8	389-395	cortex	_
2-9	396-397	(	_
2-10	398-401	PFC	_
2-11	402-403	)	_
2-12	404-406	is	_
2-13	407-415	required	_
2-14	416-419	for	_
2-15	420-432	higher-order	_
2-16	433-442	cognitive	_
2-17	443-452	processes	_
2-18	453-454	,	_
2-19	455-460	which	_
2-20	461-464	are	_
2-21	465-470	often	_
2-22	471-479	impaired	_
2-23	480-482	in	_
2-24	483-496	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
2-25	497-498	.	_

Text=To address this gap, we investigated how thalamus function and thalamus-PFC connectivity under different levels of cognitive demand may be disrupted in schizophrenia.
3-1	499-501	To	_
3-2	502-509	address	_
3-3	510-514	this	_
3-4	515-518	gap	_
3-5	519-520	,	_
3-6	521-523	we	_
3-7	524-536	investigated	_
3-8	537-540	how	_
3-9	541-549	thalamus	_
3-10	550-558	function	_
3-11	559-562	and	_
3-12	563-575	thalamus-PFC	_
3-13	576-588	connectivity	_
3-14	589-594	under	_
3-15	595-604	different	_
3-16	605-611	levels	_
3-17	612-614	of	_
3-18	615-624	cognitive	_
3-19	625-631	demand	_
3-20	632-635	may	_
3-21	636-638	be	_
3-22	639-648	disrupted	_
3-23	649-651	in	_
3-24	652-665	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
3-25	666-667	.	_

Text=Participants underwent fMRI scanning while performing an event-related two-alternative forced choice task under Single and Dual task conditions.
4-1	668-680	Participants	_
4-2	681-690	underwent	_
4-3	691-695	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
4-4	696-704	scanning	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
4-5	705-710	while	_
4-6	711-721	performing	_
4-7	722-724	an	_
4-8	725-738	event-related	_
4-9	739-754	two-alternative	_
4-10	755-761	forced	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
4-11	762-768	choice	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
4-12	769-773	task	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
4-13	774-779	under	_
4-14	780-786	Single	_
4-15	787-790	and	_
4-16	791-795	Dual	_
4-17	796-800	task	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
4-18	801-811	conditions	_
4-19	812-813	.	_

Text=In the Single task condition, participants responded either to a visual cue with a well-learned motor response, or an audio cue with a well-learned vocal response.
5-1	814-816	In	_
5-2	817-820	the	_
5-3	821-827	Single	_
5-4	828-832	task	_
5-5	833-842	condition	_
5-6	843-844	,	_
5-7	845-857	participants	_
5-8	858-867	responded	_
5-9	868-874	either	_
5-10	875-877	to	_
5-11	878-879	a	_
5-12	880-886	visual	_
5-13	887-890	cue	_
5-14	891-895	with	_
5-15	896-897	a	_
5-16	898-910	well-learned	_
5-17	911-916	motor	_
5-18	917-925	response	_
5-19	926-927	,	_
5-20	928-930	or	_
5-21	931-933	an	_
5-22	934-939	audio	_
5-23	940-943	cue	_
5-24	944-948	with	_
5-25	949-950	a	_
5-26	951-963	well-learned	_
5-27	964-969	vocal	_
5-28	970-978	response	_
5-29	979-980	.	_

Text=In the Dual task condition, participants performed both tasks.
6-1	981-983	In	_
6-2	984-987	the	_
6-3	988-992	Dual	_
6-4	993-997	task	_
6-5	998-1007	condition	_
6-6	1008-1009	,	_
6-7	1010-1022	participants	_
6-8	1023-1032	performed	_
6-9	1033-1037	both	_
6-10	1038-1043	tasks	_
6-11	1044-1045	.	_

Text=Thalamic connectivity with task relevant regions of the PFC for each condition was measured using beta-series correlation.
7-1	1046-1054	Thalamic	_
7-2	1055-1067	connectivity	_
7-3	1068-1072	with	_
7-4	1073-1077	task	_
7-5	1078-1086	relevant	_
7-6	1087-1094	regions	_
7-7	1095-1097	of	_
7-8	1098-1101	the	_
7-9	1102-1105	PFC	_
7-10	1106-1109	for	_
7-11	1110-1114	each	_
7-12	1115-1124	condition	_
7-13	1125-1128	was	_
7-14	1129-1137	measured	_
7-15	1138-1143	using	_
7-16	1144-1155	beta-series	_
7-17	1156-1167	correlation	_
7-18	1168-1169	.	_

Text=Individuals with schizophrenia demonstrated less modulation of both mediodorsal thalamus activation and thalamus-PFC connectivity with increased cognitive demand.
8-1	1170-1181	Individuals	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
8-2	1182-1186	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
8-3	1187-1200	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
8-4	1201-1213	demonstrated	_
8-5	1214-1218	less	_
8-6	1219-1229	modulation	_
8-7	1230-1232	of	_
8-8	1233-1237	both	_
8-9	1238-1249	mediodorsal	_
8-10	1250-1258	thalamus	_
8-11	1259-1269	activation	_
8-12	1270-1273	and	_
8-13	1274-1286	thalamus-PFC	_
8-14	1287-1299	connectivity	_
8-15	1300-1304	with	_
8-16	1305-1314	increased	_
8-17	1315-1324	cognitive	_
8-18	1325-1331	demand	_
8-19	1332-1333	.	_

Text=In contrast, their ability to modulate PFC function during task performance was maintained.
9-1	1334-1336	In	_
9-2	1337-1345	contrast	_
9-3	1346-1347	,	_
9-4	1348-1353	their	_
9-5	1354-1361	ability	_
9-6	1362-1364	to	_
9-7	1365-1373	modulate	_
9-8	1374-1377	PFC	_
9-9	1378-1386	function	_
9-10	1387-1393	during	_
9-11	1394-1398	task	_
9-12	1399-1410	performance	_
9-13	1411-1414	was	_
9-14	1415-1425	maintained	_
9-15	1426-1427	.	_

Text=These results suggest that the pathophysiology of cognitive impairment in schizophrenia is associated with thalamus-PFC circuitry and suggests that the thalamus, along with the PFC, should be a focus of investigation.
10-1	1428-1433	These	_
10-2	1434-1441	results	_
10-3	1442-1449	suggest	_
10-4	1450-1454	that	_
10-5	1455-1458	the	_
10-6	1459-1474	pathophysiology	_
10-7	1475-1477	of	_
10-8	1478-1487	cognitive	_
10-9	1488-1498	impairment	_
10-10	1499-1501	in	_
10-11	1502-1515	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
10-12	1516-1518	is	_
10-13	1519-1529	associated	_
10-14	1530-1534	with	_
10-15	1535-1547	thalamus-PFC	_
10-16	1548-1557	circuitry	_
10-17	1558-1561	and	_
10-18	1562-1570	suggests	_
10-19	1571-1575	that	_
10-20	1576-1579	the	_
10-21	1580-1588	thalamus	_
10-22	1589-1590	,	_
10-23	1591-1596	along	_
10-24	1597-1601	with	_
10-25	1602-1605	the	_
10-26	1606-1609	PFC	_
10-27	1610-1611	,	_
10-28	1612-1618	should	_
10-29	1619-1621	be	_
10-30	1622-1623	a	_
10-31	1624-1629	focus	_
10-32	1630-1632	of	_
10-33	1633-1646	investigation	_
10-34	1647-1648	.	_

Text=Method Participants Twenty-two patients with schizophrenia and 24 healthy individuals matched for age, gender, ethnicity and parental education participated in this study.
11-1	1649-1655	Method	_
11-2	1656-1668	Participants	_
11-3	1669-1679	Twenty-two	_
11-4	1680-1688	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
11-5	1689-1693	with	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
11-6	1694-1707	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
11-7	1708-1711	and	_
11-8	1712-1714	24	_
11-9	1715-1722	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
11-10	1723-1734	individuals	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
11-11	1735-1742	matched	_
11-12	1743-1746	for	_
11-13	1747-1750	age	_
11-14	1751-1752	,	_
11-15	1753-1759	gender	_
11-16	1760-1761	,	_
11-17	1762-1771	ethnicity	_
11-18	1772-1775	and	_
11-19	1776-1784	parental	_
11-20	1785-1794	education	_
11-21	1795-1807	participated	_
11-22	1808-1810	in	_
11-23	1811-1815	this	_
11-24	1816-1821	study	_
11-25	1822-1823	.	_

Text=6 subjects (4 healthy; 2 schizophrenia) were excluded for incomplete data and one healthy individual was removed for excessive head motion.
12-1	1824-1825	6	_
12-2	1826-1834	subjects	_
12-3	1835-1836	(	_
12-4	1837-1838	4	_
12-5	1839-1846	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
12-6	1847-1848	;	_
12-7	1849-1850	2	_
12-8	1851-1864	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
12-9	1865-1866	)	_
12-10	1867-1871	were	_
12-11	1872-1880	excluded	_
12-12	1881-1884	for	_
12-13	1885-1895	incomplete	_
12-14	1896-1900	data	_
12-15	1901-1904	and	_
12-16	1905-1908	one	_
12-17	1909-1916	healthy	_
12-18	1917-1927	individual	_
12-19	1928-1931	was	_
12-20	1932-1939	removed	_
12-21	1940-1943	for	_
12-22	1944-1953	excessive	_
12-23	1954-1958	head	_
12-24	1959-1965	motion	_
12-25	1966-1967	.	_

Text=Thus, the final sample included 20 schizophrenia patients and 19 healthy individuals.
13-1	1968-1972	Thus	_
13-2	1973-1974	,	_
13-3	1975-1978	the	_
13-4	1979-1984	final	_
13-5	1985-1991	sample	_
13-6	1992-2000	included	_
13-7	2001-2003	20	_
13-8	2004-2017	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
13-9	2018-2026	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
13-10	2027-2030	and	_
13-11	2031-2033	19	_
13-12	2034-2041	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
13-13	2042-2053	individuals	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
13-14	2054-2055	.	_

Text=Demographics for subjects included in the analyses are presented in Table 1.
14-1	2056-2068	Demographics	_
14-2	2069-2072	for	_
14-3	2073-2081	subjects	_
14-4	2082-2090	included	_
14-5	2091-2093	in	_
14-6	2094-2097	the	_
14-7	2098-2106	analyses	_
14-8	2107-2110	are	_
14-9	2111-2120	presented	_
14-10	2121-2123	in	_
14-11	2124-2129	Table	_
14-12	2130-2131	1	_
14-13	2132-2133	.	_

Text=Schizophrenia participants were recruited from inpatient and outpatient services at the Vanderbilt Psychiatric Hospital in Nashville, Tennessee, and healthy participants were recruited from Nashville and the surrounding area through advertisement and word-of-mouth.
15-1	2134-2147	Schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
15-2	2148-2160	participants	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
15-3	2161-2165	were	_
15-4	2166-2175	recruited	_
15-5	2176-2180	from	_
15-6	2181-2190	inpatient	_
15-7	2191-2194	and	_
15-8	2195-2205	outpatient	_
15-9	2206-2214	services	_
15-10	2215-2217	at	_
15-11	2218-2221	the	_
15-12	2222-2232	Vanderbilt	_
15-13	2233-2244	Psychiatric	_
15-14	2245-2253	Hospital	_
15-15	2254-2256	in	_
15-16	2257-2266	Nashville	_
15-17	2267-2268	,	_
15-18	2269-2278	Tennessee	_
15-19	2279-2280	,	_
15-20	2281-2284	and	_
15-21	2285-2292	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
15-22	2293-2305	participants	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
15-23	2306-2310	were	_
15-24	2311-2320	recruited	_
15-25	2321-2325	from	_
15-26	2326-2335	Nashville	_
15-27	2336-2339	and	_
15-28	2340-2343	the	_
15-29	2344-2355	surrounding	_
15-30	2356-2360	area	_
15-31	2361-2368	through	_
15-32	2369-2382	advertisement	_
15-33	2383-2386	and	_
15-34	2387-2400	word-of-mouth	_
15-35	2401-2402	.	_

Text=Our schizophrenia sample consisted of 17 outpatients and 2 inpatients (data from 1 participant was not available).
16-1	2403-2406	Our	_
16-2	2407-2420	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
16-3	2421-2427	sample	_
16-4	2428-2437	consisted	_
16-5	2438-2440	of	_
16-6	2441-2443	17	_
16-7	2444-2455	outpatients	http://maven.renci.org/NeuroBridge/neurobridge#FullScaleIntelligenceQuotient
16-8	2456-2459	and	_
16-9	2460-2461	2	_
16-10	2462-2472	inpatients	http://maven.renci.org/NeuroBridge/neurobridge#Agent
16-11	2473-2474	(	_
16-12	2475-2479	data	_
16-13	2480-2484	from	_
16-14	2485-2486	1	_
16-15	2487-2498	participant	_
16-16	2499-2502	was	_
16-17	2503-2506	not	_
16-18	2507-2516	available	_
16-19	2517-2518	)	_
16-20	2519-2520	.	_

Text=One patient was unmedicated and 2 were not receiving any antipsychotic medications.
17-1	2521-2524	One	_
17-2	2525-2532	patient	_
17-3	2533-2536	was	_
17-4	2537-2548	unmedicated	_
17-5	2549-2552	and	_
17-6	2553-2554	2	_
17-7	2555-2559	were	_
17-8	2560-2563	not	_
17-9	2564-2573	receiving	_
17-10	2574-2577	any	_
17-11	2578-2591	antipsychotic	_
17-12	2592-2603	medications	_
17-13	2604-2605	.	_

Text=This study was approved by the Vanderbilt University Institutional Review Board and all participants provided written informed consent prior to participating in this study.
18-1	2606-2610	This	_
18-2	2611-2616	study	_
18-3	2617-2620	was	_
18-4	2621-2629	approved	_
18-5	2630-2632	by	_
18-6	2633-2636	the	_
18-7	2637-2647	Vanderbilt	_
18-8	2648-2658	University	_
18-9	2659-2672	Institutional	_
18-10	2673-2679	Review	_
18-11	2680-2685	Board	_
18-12	2686-2689	and	_
18-13	2690-2693	all	_
18-14	2694-2706	participants	_
18-15	2707-2715	provided	_
18-16	2716-2723	written	_
18-17	2724-2732	informed	_
18-18	2733-2740	consent	_
18-19	2741-2746	prior	_
18-20	2747-2749	to	_
18-21	2750-2763	participating	_
18-22	2764-2766	in	_
18-23	2767-2771	this	_
18-24	2772-2777	study	_
18-25	2778-2779	.	_

Text=All participants were administered the Structured Clinical Interview for Diagnosing DSM-IV Disorders (SCID:) to confirm diagnosis in patients and rule out current or past psychiatric illness in control subjects.
19-1	2780-2783	All	_
19-2	2784-2796	participants	_
19-3	2797-2801	were	_
19-4	2802-2814	administered	_
19-5	2815-2818	the	_
19-6	2819-2829	Structured	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
19-7	2830-2838	Clinical	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
19-8	2839-2848	Interview	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
19-9	2849-2852	for	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
19-10	2853-2863	Diagnosing	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
19-11	2864-2870	DSM-IV	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
19-12	2871-2880	Disorders	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
19-13	2881-2882	(	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
19-14	2883-2887	SCID	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
19-15	2888-2889	:	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
19-16	2890-2891	)	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
19-17	2892-2894	to	_
19-18	2895-2902	confirm	_
19-19	2903-2912	diagnosis	_
19-20	2913-2915	in	_
19-21	2916-2924	patients	_
19-22	2925-2928	and	_
19-23	2929-2933	rule	_
19-24	2934-2937	out	_
19-25	2938-2945	current	_
19-26	2946-2948	or	_
19-27	2949-2953	past	_
19-28	2954-2965	psychiatric	_
19-29	2966-2973	illness	_
19-30	2974-2976	in	_
19-31	2977-2984	control	_
19-32	2985-2993	subjects	_
19-33	2994-2995	.	_

Text=Clinical symptoms in patients were quantified with the Positive and Negative Syndrome Scale (PANSS:).
20-1	2996-3004	Clinical	_
20-2	3005-3013	symptoms	_
20-3	3014-3016	in	_
20-4	3017-3025	patients	_
20-5	3026-3030	were	_
20-6	3031-3041	quantified	_
20-7	3042-3046	with	_
20-8	3047-3050	the	_
20-9	3051-3059	Positive	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
20-10	3060-3063	and	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
20-11	3064-3072	Negative	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
20-12	3073-3081	Syndrome	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
20-13	3082-3087	Scale	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
20-14	3088-3089	(	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
20-15	3090-3095	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
20-16	3096-3097	:	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
20-17	3098-3099	)	http://maven.renci.org/NeuroBridge/neurobridge#PositiveandNegativeSyndromeScale
20-18	3100-3101	.	_

Text=Premorbid IQ was estimated using the Wechsler Test of Adult Reading (WTAR:).
21-1	3102-3111	Premorbid	_
21-2	3112-3114	IQ	_
21-3	3115-3118	was	_
21-4	3119-3128	estimated	_
21-5	3129-3134	using	_
21-6	3135-3138	the	_
21-7	3139-3147	Wechsler	http://maven.renci.org/NeuroBridge/neurobridge#NationalAdultReadingTest
21-8	3148-3152	Test	http://maven.renci.org/NeuroBridge/neurobridge#NationalAdultReadingTest
21-9	3153-3155	of	http://maven.renci.org/NeuroBridge/neurobridge#NationalAdultReadingTest
21-10	3156-3161	Adult	http://maven.renci.org/NeuroBridge/neurobridge#NationalAdultReadingTest
21-11	3162-3169	Reading	http://maven.renci.org/NeuroBridge/neurobridge#NationalAdultReadingTest
21-12	3170-3171	(	_
21-13	3172-3176	WTAR	_
21-14	3177-3178	:	_
21-15	3179-3180	)	_
21-16	3181-3182	.	_

Text=Exclusion criteria included an estimated premorbid IQ of less than 70, age less than 18 or greater than 60, presence of a systemic medical illness (i.e.
22-1	3183-3192	Exclusion	_
22-2	3193-3201	criteria	_
22-3	3202-3210	included	_
22-4	3211-3213	an	_
22-5	3214-3223	estimated	_
22-6	3224-3233	premorbid	_
22-7	3234-3236	IQ	_
22-8	3237-3239	of	_
22-9	3240-3244	less	_
22-10	3245-3249	than	_
22-11	3250-3252	70	_
22-12	3253-3254	,	_
22-13	3255-3258	age	_
22-14	3259-3263	less	_
22-15	3264-3268	than	_
22-16	3269-3271	18	_
22-17	3272-3274	or	_
22-18	3275-3282	greater	_
22-19	3283-3287	than	_
22-20	3288-3290	60	_
22-21	3291-3292	,	_
22-22	3293-3301	presence	_
22-23	3302-3304	of	_
22-24	3305-3306	a	_
22-25	3307-3315	systemic	_
22-26	3316-3323	medical	_
22-27	3324-3331	illness	_
22-28	3332-3333	(	_
22-29	3334-3337	i.e	_
22-30	3338-3339	.	_

Text=diabetes, cardiovascular or central nervous system disorder that would affect study participation, history of significant head trauma, reported pregnancy or lactation, history of substance abuse/dependence (3-months in patients; lifetime in controls), psychotropic drug use (in healthy individuals), and any MRI contraindications (e.g.
23-1	3340-3348	diabetes	_
23-2	3349-3350	,	_
23-3	3351-3365	cardiovascular	_
23-4	3366-3368	or	_
23-5	3369-3376	central	_
23-6	3377-3384	nervous	_
23-7	3385-3391	system	_
23-8	3392-3400	disorder	_
23-9	3401-3405	that	_
23-10	3406-3411	would	_
23-11	3412-3418	affect	_
23-12	3419-3424	study	_
23-13	3425-3438	participation	_
23-14	3439-3440	,	_
23-15	3441-3448	history	_
23-16	3449-3451	of	_
23-17	3452-3463	significant	_
23-18	3464-3468	head	_
23-19	3469-3475	trauma	_
23-20	3476-3477	,	_
23-21	3478-3486	reported	_
23-22	3487-3496	pregnancy	_
23-23	3497-3499	or	_
23-24	3500-3509	lactation	_
23-25	3510-3511	,	_
23-26	3512-3519	history	_
23-27	3520-3522	of	_
23-28	3523-3532	substance	_
23-29	3533-3549	abuse/dependence	_
23-30	3550-3551	(	_
23-31	3552-3560	3-months	_
23-32	3561-3563	in	_
23-33	3564-3572	patients	_
23-34	3573-3574	;	_
23-35	3575-3583	lifetime	_
23-36	3584-3586	in	_
23-37	3587-3595	controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
23-38	3596-3597	)	_
23-39	3598-3599	,	_
23-40	3600-3612	psychotropic	_
23-41	3613-3617	drug	_
23-42	3618-3621	use	_
23-43	3622-3623	(	_
23-44	3624-3626	in	_
23-45	3627-3634	healthy	_
23-46	3635-3646	individuals	_
23-47	3647-3648	)	_
23-48	3649-3650	,	_
23-49	3651-3654	and	_
23-50	3655-3658	any	_
23-51	3659-3662	MRI	_
23-52	3663-3680	contraindications	_
23-53	3681-3682	(	_
23-54	3683-3686	e.g	_
23-55	3687-3688	.	_

Text=metal implants, claustrophobia).
24-1	3689-3694	metal	_
24-2	3695-3703	implants	_
24-3	3704-3705	,	_
24-4	3706-3720	claustrophobia	_
24-5	3721-3722	)	_
24-6	3723-3724	.	_

Text=Task On each trial, participants performed either a visuo-motor task where a visual cue was mapped to a motor response, or an audio-vocal task where an audio cue was mapped to a vocal response (Single task condition), or both tasks with a 0 ms stimulus onset asynchrony (Dual task condition).
25-1	3725-3729	Task	_
25-2	3730-3732	On	_
25-3	3733-3737	each	_
25-4	3738-3743	trial	_
25-5	3744-3745	,	_
25-6	3746-3758	participants	_
25-7	3759-3768	performed	_
25-8	3769-3775	either	_
25-9	3776-3777	a	_
25-10	3778-3789	visuo-motor	_
25-11	3790-3794	task	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
25-12	3795-3800	where	_
25-13	3801-3802	a	_
25-14	3803-3809	visual	_
25-15	3810-3813	cue	_
25-16	3814-3817	was	_
25-17	3818-3824	mapped	_
25-18	3825-3827	to	_
25-19	3828-3829	a	_
25-20	3830-3835	motor	_
25-21	3836-3844	response	_
25-22	3845-3846	,	_
25-23	3847-3849	or	_
25-24	3850-3852	an	_
25-25	3853-3864	audio-vocal	_
25-26	3865-3869	task	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
25-27	3870-3875	where	_
25-28	3876-3878	an	_
25-29	3879-3884	audio	_
25-30	3885-3888	cue	_
25-31	3889-3892	was	_
25-32	3893-3899	mapped	_
25-33	3900-3902	to	_
25-34	3903-3904	a	_
25-35	3905-3910	vocal	_
25-36	3911-3919	response	_
25-37	3920-3921	(	_
25-38	3922-3928	Single	_
25-39	3929-3933	task	_
25-40	3934-3943	condition	_
25-41	3944-3945	)	_
25-42	3946-3947	,	_
25-43	3948-3950	or	_
25-44	3951-3955	both	_
25-45	3956-3961	tasks	_
25-46	3962-3966	with	_
25-47	3967-3968	a	_
25-48	3969-3970	0	_
25-49	3971-3973	ms	_
25-50	3974-3982	stimulus	_
25-51	3983-3988	onset	_
25-52	3989-3999	asynchrony	_
25-53	4000-4001	(	_
25-54	4002-4006	Dual	_
25-55	4007-4011	task	_
25-56	4012-4021	condition	_
25-57	4022-4023	)	_
25-58	4024-4025	.	_

Text=Both visuo-motor and audio-vocal tasks were two-alternative forced choice tasks, mapping two stimuli to two responses.
26-1	4026-4030	Both	_
26-2	4031-4042	visuo-motor	_
26-3	4043-4046	and	_
26-4	4047-4058	audio-vocal	_
26-5	4059-4064	tasks	_
26-6	4065-4069	were	_
26-7	4070-4085	two-alternative	_
26-8	4086-4092	forced	_
26-9	4093-4099	choice	_
26-10	4100-4105	tasks	_
26-11	4106-4107	,	_
26-12	4108-4115	mapping	_
26-13	4116-4119	two	_
26-14	4120-4127	stimuli	_
26-15	4128-4130	to	_
26-16	4131-4134	two	_
26-17	4135-4144	responses	_
26-18	4145-4146	.	_

Text=The visual stimuli were two greyscale male faces controlled for skin tone, hair color, neutral facial expression and hairline on a grey background.
27-1	4147-4150	The	_
27-2	4151-4157	visual	_
27-3	4158-4165	stimuli	_
27-4	4166-4170	were	_
27-5	4171-4174	two	_
27-6	4175-4184	greyscale	_
27-7	4185-4189	male	_
27-8	4190-4195	faces	_
27-9	4196-4206	controlled	_
27-10	4207-4210	for	_
27-11	4211-4215	skin	_
27-12	4216-4220	tone	_
27-13	4221-4222	,	_
27-14	4223-4227	hair	_
27-15	4228-4233	color	_
27-16	4234-4235	,	_
27-17	4236-4243	neutral	_
27-18	4244-4250	facial	_
27-19	4251-4261	expression	_
27-20	4262-4265	and	_
27-21	4266-4274	hairline	_
27-22	4275-4277	on	_
27-23	4278-4279	a	_
27-24	4280-4284	grey	_
27-25	4285-4295	background	_
27-26	4296-4297	.	_

Text=Participants responded to each face by pressing a button with either their right index or middle finger.
28-1	4298-4310	Participants	_
28-2	4311-4320	responded	_
28-3	4321-4323	to	_
28-4	4324-4328	each	_
28-5	4329-4333	face	_
28-6	4334-4336	by	_
28-7	4337-4345	pressing	_
28-8	4346-4347	a	_
28-9	4348-4354	button	_
28-10	4355-4359	with	_
28-11	4360-4366	either	_
28-12	4367-4372	their	_
28-13	4373-4378	right	_
28-14	4379-4384	index	_
28-15	4385-4387	or	_
28-16	4388-4394	middle	_
28-17	4395-4401	finger	_
28-18	4402-4403	.	_

Text=The audio-vocal task consisted of two easily discriminable sounds (a complex tone and an edited natural sound) used previously in, each paired with a “ Tay ” or a “ Koo ” vocal response.
29-1	4404-4407	The	_
29-2	4408-4419	audio-vocal	_
29-3	4420-4424	task	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
29-4	4425-4434	consisted	_
29-5	4435-4437	of	_
29-6	4438-4441	two	_
29-7	4442-4448	easily	_
29-8	4449-4462	discriminable	_
29-9	4463-4469	sounds	_
29-10	4470-4471	(	_
29-11	4472-4473	a	_
29-12	4474-4481	complex	_
29-13	4482-4486	tone	_
29-14	4487-4490	and	_
29-15	4491-4493	an	_
29-16	4494-4500	edited	_
29-17	4501-4508	natural	_
29-18	4509-4514	sound	_
29-19	4515-4516	)	_
29-20	4517-4521	used	_
29-21	4522-4532	previously	_
29-22	4533-4535	in	_
29-23	4536-4537	,	_
29-24	4538-4542	each	_
29-25	4543-4549	paired	_
29-26	4550-4554	with	_
29-27	4555-4556	a	_
29-28	4557-4558	“	_
29-29	4559-4562	Tay	_
29-30	4563-4564	”	_
29-31	4565-4567	or	_
29-32	4568-4569	a	_
29-33	4570-4571	“	_
29-34	4572-4575	Koo	_
29-35	4576-4577	”	_
29-36	4578-4583	vocal	_
29-37	4584-4592	response	_
29-38	4593-4594	.	_

Text=On Single trials, one visual or auditory stimulus was presented for 200 ms, on Dual trials, both the visual and auditory stimuli were presented simultaneously.
30-1	4595-4597	On	_
30-2	4598-4604	Single	_
30-3	4605-4611	trials	_
30-4	4612-4613	,	_
30-5	4614-4617	one	_
30-6	4618-4624	visual	_
30-7	4625-4627	or	_
30-8	4628-4636	auditory	_
30-9	4637-4645	stimulus	_
30-10	4646-4649	was	_
30-11	4650-4659	presented	_
30-12	4660-4663	for	_
30-13	4664-4667	200	_
30-14	4668-4670	ms	_
30-15	4671-4672	,	_
30-16	4673-4675	on	_
30-17	4676-4680	Dual	_
30-18	4681-4687	trials	_
30-19	4688-4689	,	_
30-20	4690-4694	both	_
30-21	4695-4698	the	_
30-22	4699-4705	visual	_
30-23	4706-4709	and	_
30-24	4710-4718	auditory	_
30-25	4719-4726	stimuli	_
30-26	4727-4731	were	_
30-27	4732-4741	presented	_
30-28	4742-4756	simultaneously	_
30-29	4757-4758	.	_

Text=All trials were preceded by a 200 ms warning fixation and followed by a 12000 ms inter-trial interval (see Figure 1A for schematic).
31-1	4759-4762	All	_
31-2	4763-4769	trials	_
31-3	4770-4774	were	_
31-4	4775-4783	preceded	_
31-5	4784-4786	by	_
31-6	4787-4788	a	_
31-7	4789-4792	200	_
31-8	4793-4795	ms	_
31-9	4796-4803	warning	_
31-10	4804-4812	fixation	_
31-11	4813-4816	and	_
31-12	4817-4825	followed	_
31-13	4826-4828	by	_
31-14	4829-4830	a	_
31-15	4831-4836	12000	_
31-16	4837-4839	ms	_
31-17	4840-4851	inter-trial	_
31-18	4852-4860	interval	_
31-19	4861-4862	(	_
31-20	4863-4866	see	_
31-21	4867-4873	Figure	_
31-22	4874-4876	1A	_
31-23	4877-4880	for	_
31-24	4881-4890	schematic	_
31-25	4891-4892	)	_
31-26	4893-4894	.	_

Text=Participants completed a total of 5 runs while undergoing fMRI scanning with each run consisting of 12 Single (6 visuomotor and 6 audio-vocal) and 12 Dual trials.
32-1	4895-4907	Participants	_
32-2	4908-4917	completed	_
32-3	4918-4919	a	_
32-4	4920-4925	total	_
32-5	4926-4928	of	_
32-6	4929-4930	5	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
32-7	4931-4935	runs	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
32-8	4936-4941	while	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
32-9	4942-4952	undergoing	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
32-10	4953-4957	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
32-11	4958-4966	scanning	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
32-12	4967-4971	with	_
32-13	4972-4976	each	_
32-14	4977-4980	run	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
32-15	4981-4991	consisting	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
32-16	4992-4994	of	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
32-17	4995-4997	12	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
32-18	4998-5004	Single	http://maven.renci.org/NeuroBridge/neurobridge#SinglePhotonImaging
32-19	5005-5006	(	_
32-20	5007-5008	6	_
32-21	5009-5019	visuomotor	_
32-22	5020-5023	and	_
32-23	5024-5025	6	_
32-24	5026-5037	audio-vocal	_
32-25	5038-5039	)	_
32-26	5040-5043	and	_
32-27	5044-5046	12	_
32-28	5047-5051	Dual	http://maven.renci.org/NeuroBridge/neurobridge#DualEnergyXRayAbsorptiometry
32-29	5052-5058	trials	http://maven.renci.org/NeuroBridge/neurobridge#DualEnergyXRayAbsorptiometry
32-30	5059-5060	.	_

Text=Data acquisition Imaging data were collected on a 3T Philips Intera Achieva scanner located at the Vanderbilt University Institute of Imaging Science.
33-1	5061-5065	Data	_
33-2	5066-5077	acquisition	_
33-3	5078-5085	Imaging	_
33-4	5086-5090	data	_
33-5	5091-5095	were	_
33-6	5096-5105	collected	_
33-7	5106-5108	on	_
33-8	5109-5110	a	_
33-9	5111-5113	3T	http://maven.renci.org/NeuroBridge/neurobridge#WideRangeAchievementTest
33-10	5114-5121	Philips	http://maven.renci.org/NeuroBridge/neurobridge#WideRangeAchievementTest
33-11	5122-5128	Intera	http://maven.renci.org/NeuroBridge/neurobridge#WideRangeAchievementTest
33-12	5129-5136	Achieva	http://maven.renci.org/NeuroBridge/neurobridge#WideRangeAchievementTest
33-13	5137-5144	scanner	_
33-14	5145-5152	located	_
33-15	5153-5155	at	_
33-16	5156-5159	the	_
33-17	5160-5170	Vanderbilt	_
33-18	5171-5181	University	_
33-19	5182-5191	Institute	_
33-20	5192-5194	of	_
33-21	5195-5202	Imaging	_
33-22	5203-5210	Science	_
33-23	5211-5212	.	_

Text=High resolution T1 structural scans were collected with a 4.5 minute 3D T1 fast field echo sequence (170 slices, TR/TE = 8.9/4.6, FOV = 256 × 256 × 170 mm, matrix = 256 × 256 × 170, flip angle = 8°).
34-1	5213-5217	High	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk
34-2	5218-5228	resolution	http://maven.renci.org/NeuroBridge/neurobridge#HighRisk
34-3	5229-5231	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
34-4	5232-5242	structural	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
34-5	5243-5248	scans	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
34-6	5249-5253	were	_
34-7	5254-5263	collected	_
34-8	5264-5268	with	_
34-9	5269-5270	a	_
34-10	5271-5274	4.5	_
34-11	5275-5281	minute	_
34-12	5282-5284	3D	_
34-13	5285-5287	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
34-14	5288-5292	fast	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
34-15	5293-5298	field	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
34-16	5299-5303	echo	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
34-17	5304-5312	sequence	_
34-18	5313-5314	(	_
34-19	5315-5318	170	_
34-20	5319-5325	slices	_
34-21	5326-5327	,	_
34-22	5328-5333	TR/TE	_
34-23	5334-5335	=	_
34-24	5336-5343	8.9/4.6	_
34-25	5344-5345	,	_
34-26	5346-5349	FOV	_
34-27	5350-5351	=	_
34-28	5352-5355	256	_
34-29	5356-5357	×	_
34-30	5358-5361	256	_
34-31	5362-5363	×	_
34-32	5364-5367	170	_
34-33	5368-5370	mm	_
34-34	5371-5372	,	_
34-35	5373-5379	matrix	_
34-36	5380-5381	=	_
34-37	5382-5385	256	_
34-38	5386-5387	×	_
34-39	5388-5391	256	_
34-40	5392-5393	×	_
34-41	5394-5397	170	_
34-42	5398-5399	,	_
34-43	5400-5404	flip	_
34-44	5405-5410	angle	_
34-45	5411-5412	=	_
34-46	5413-5415	8°	_
34-47	5416-5417	)	_
34-48	5418-5419	.	_

Text=Echo-planar imaging functional scans were collected while participants performed the behavioral task (38 slices, TR/TE = 2000/25 ms, FOV = 240 × 240 mm, matrix = 80 × 80, slice thickness = 3 mm with 0.3 mm gap, flip angle = 90°, volumes = 203).
35-1	5420-5431	Echo-planar	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
35-2	5432-5439	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
35-3	5440-5450	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
35-4	5451-5456	scans	_
35-5	5457-5461	were	_
35-6	5462-5471	collected	_
35-7	5472-5477	while	_
35-8	5478-5490	participants	_
35-9	5491-5500	performed	_
35-10	5501-5504	the	_
35-11	5505-5515	behavioral	http://maven.renci.org/NeuroBridge/neurobridge#BehavioralActivationScale
35-12	5516-5520	task	http://maven.renci.org/NeuroBridge/neurobridge#BehavioralActivationScale
35-13	5521-5522	(	_
35-14	5523-5525	38	_
35-15	5526-5532	slices	_
35-16	5533-5534	,	_
35-17	5535-5540	TR/TE	_
35-18	5541-5542	=	_
35-19	5543-5550	2000/25	_
35-20	5551-5553	ms	_
35-21	5554-5555	,	_
35-22	5556-5559	FOV	_
35-23	5560-5561	=	_
35-24	5562-5565	240	_
35-25	5566-5567	×	_
35-26	5568-5571	240	_
35-27	5572-5574	mm	_
35-28	5575-5576	,	_
35-29	5577-5583	matrix	_
35-30	5584-5585	=	_
35-31	5586-5588	80	_
35-32	5589-5590	×	_
35-33	5591-5593	80	_
35-34	5594-5595	,	_
35-35	5596-5601	slice	_
35-36	5602-5611	thickness	_
35-37	5612-5613	=	_
35-38	5614-5615	3	_
35-39	5616-5618	mm	_
35-40	5619-5623	with	_
35-41	5624-5627	0.3	_
35-42	5628-5630	mm	_
35-43	5631-5634	gap	_
35-44	5635-5636	,	_
35-45	5637-5641	flip	_
35-46	5642-5647	angle	_
35-47	5648-5649	=	_
35-48	5650-5653	90°	_
35-49	5654-5655	,	_
35-50	5656-5663	volumes	_
35-51	5664-5665	=	_
35-52	5666-5669	203	_
35-53	5670-5671	)	_
35-54	5672-5673	.	_

Text=Data analyses Neuroimaging preprocessing and subsequent analyses were carried out using SPM12 (version 7219) in Matlab (R2017b; MathWorks, USA).
36-1	5674-5678	Data	_
36-2	5679-5687	analyses	_
36-3	5688-5700	Neuroimaging	_
36-4	5701-5714	preprocessing	_
36-5	5715-5718	and	_
36-6	5719-5729	subsequent	_
36-7	5730-5738	analyses	_
36-8	5739-5743	were	_
36-9	5744-5751	carried	_
36-10	5752-5755	out	_
36-11	5756-5761	using	_
36-12	5762-5767	SPM12	_
36-13	5768-5769	(	_
36-14	5770-5777	version	_
36-15	5778-5782	7219	_
36-16	5783-5784	)	_
36-17	5785-5787	in	_
36-18	5788-5794	Matlab	_
36-19	5795-5796	(	_
36-20	5797-5803	R2017b	_
36-21	5804-5805	;	_
36-22	5806-5815	MathWorks	_
36-23	5816-5817	,	_
36-24	5818-5821	USA	_
36-25	5822-5823	)	_
36-26	5824-5825	.	_

Text=T1 structural images were skull stripped then segmented into grey and white matter tissue classes and normalized to MNI space using the CAT12 computational anatomy toolbox for SPM with default settings.
37-1	5826-5828	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
37-2	5829-5839	structural	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
37-3	5840-5846	images	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
37-4	5847-5851	were	_
37-5	5852-5857	skull	_
37-6	5858-5866	stripped	_
37-7	5867-5871	then	_
37-8	5872-5881	segmented	_
37-9	5882-5886	into	_
37-10	5887-5891	grey	_
37-11	5892-5895	and	_
37-12	5896-5901	white	_
37-13	5902-5908	matter	_
37-14	5909-5915	tissue	_
37-15	5916-5923	classes	_
37-16	5924-5927	and	_
37-17	5928-5938	normalized	_
37-18	5939-5941	to	_
37-19	5942-5945	MNI	_
37-20	5946-5951	space	_
37-21	5952-5957	using	_
37-22	5958-5961	the	_
37-23	5962-5967	CAT12	_
37-24	5968-5981	computational	_
37-25	5982-5989	anatomy	_
37-26	5990-5997	toolbox	_
37-27	5998-6001	for	_
37-28	6002-6005	SPM	_
37-29	6006-6010	with	_
37-30	6011-6018	default	_
37-31	6019-6027	settings	_
37-32	6028-6029	.	_

Text=Functional data underwent slice timing correction, motion correction followed by co-registration to the grey matter tissue segmentation.
38-1	6030-6040	Functional	_
38-2	6041-6045	data	_
38-3	6046-6055	underwent	_
38-4	6056-6061	slice	_
38-5	6062-6068	timing	_
38-6	6069-6079	correction	_
38-7	6080-6081	,	_
38-8	6082-6088	motion	_
38-9	6089-6099	correction	_
38-10	6100-6108	followed	_
38-11	6109-6111	by	_
38-12	6112-6127	co-registration	_
38-13	6128-6130	to	_
38-14	6131-6134	the	_
38-15	6135-6139	grey	_
38-16	6140-6146	matter	_
38-17	6147-6153	tissue	_
38-18	6154-6166	segmentation	_
38-19	6167-6168	.	_

Text=Deformation parameters from the structural normalization were then applied to all functional images, which were then smoothed with a 6 mm Gaussian kernel.
39-1	6169-6180	Deformation	_
39-2	6181-6191	parameters	_
39-3	6192-6196	from	_
39-4	6197-6200	the	_
39-5	6201-6211	structural	_
39-6	6212-6225	normalization	_
39-7	6226-6230	were	_
39-8	6231-6235	then	_
39-9	6236-6243	applied	_
39-10	6244-6246	to	_
39-11	6247-6250	all	_
39-12	6251-6261	functional	_
39-13	6262-6268	images	_
39-14	6269-6270	,	_
39-15	6271-6276	which	_
39-16	6277-6281	were	_
39-17	6282-6286	then	_
39-18	6287-6295	smoothed	_
39-19	6296-6300	with	_
39-20	6301-6302	a	_
39-21	6303-6304	6	_
39-22	6305-6307	mm	_
39-23	6308-6316	Gaussian	_
39-24	6317-6323	kernel	_
39-25	6324-6325	.	_

Text=For each subject, runs with motion larger than 3 mm in the x, y or z dimensions relative to the first volume in each run were excluded from further analysis.
40-1	6326-6329	For	_
40-2	6330-6334	each	_
40-3	6335-6342	subject	_
40-4	6343-6344	,	_
40-5	6345-6349	runs	_
40-6	6350-6354	with	_
40-7	6355-6361	motion	_
40-8	6362-6368	larger	_
40-9	6369-6373	than	_
40-10	6374-6375	3	_
40-11	6376-6378	mm	_
40-12	6379-6381	in	_
40-13	6382-6385	the	_
40-14	6386-6387	x	_
40-15	6388-6389	,	_
40-16	6390-6391	y	_
40-17	6392-6394	or	_
40-18	6395-6396	z	_
40-19	6397-6407	dimensions	_
40-20	6408-6416	relative	_
40-21	6417-6419	to	_
40-22	6420-6423	the	_
40-23	6424-6429	first	_
40-24	6430-6436	volume	_
40-25	6437-6439	in	_
40-26	6440-6444	each	_
40-27	6445-6448	run	_
40-28	6449-6453	were	_
40-29	6454-6462	excluded	_
40-30	6463-6467	from	_
40-31	6468-6475	further	_
40-32	6476-6484	analysis	_
40-33	6485-6486	.	_

Text=A total of 12 runs were excluded for excessive motion, with no subject having more than 2 of their 5 runs removed.
41-1	6487-6488	A	_
41-2	6489-6494	total	_
41-3	6495-6497	of	_
41-4	6498-6500	12	_
41-5	6501-6505	runs	_
41-6	6506-6510	were	_
41-7	6511-6519	excluded	_
41-8	6520-6523	for	_
41-9	6524-6533	excessive	_
41-10	6534-6540	motion	_
41-11	6541-6542	,	_
41-12	6543-6547	with	_
41-13	6548-6550	no	_
41-14	6551-6558	subject	_
41-15	6559-6565	having	_
41-16	6566-6570	more	_
41-17	6571-6575	than	_
41-18	6576-6577	2	_
41-19	6578-6580	of	_
41-20	6581-6586	their	_
41-21	6587-6588	5	_
41-22	6589-6593	runs	_
41-23	6594-6601	removed	_
41-24	6602-6603	.	_

Text=A General Linear Model (GLM) was created for each subject with regressors defined separately for correct and incorrect Single and Dual trial onsets, convolved to a canonical hemodynamic response function.
42-1	6604-6605	A	_
42-2	6606-6613	General	_
42-3	6614-6620	Linear	_
42-4	6621-6626	Model	_
42-5	6627-6628	(	_
42-6	6629-6632	GLM	_
42-7	6633-6634	)	_
42-8	6635-6638	was	_
42-9	6639-6646	created	_
42-10	6647-6650	for	_
42-11	6651-6655	each	_
42-12	6656-6663	subject	_
42-13	6664-6668	with	_
42-14	6669-6679	regressors	_
42-15	6680-6687	defined	_
42-16	6688-6698	separately	_
42-17	6699-6702	for	_
42-18	6703-6710	correct	_
42-19	6711-6714	and	_
42-20	6715-6724	incorrect	_
42-21	6725-6731	Single	_
42-22	6732-6735	and	_
42-23	6736-6740	Dual	_
42-24	6741-6746	trial	_
42-25	6747-6753	onsets	_
42-26	6754-6755	,	_
42-27	6756-6765	convolved	_
42-28	6766-6768	to	_
42-29	6769-6770	a	_
42-30	6771-6780	canonical	_
42-31	6781-6792	hemodynamic	_
42-32	6793-6801	response	_
42-33	6802-6810	function	_
42-34	6811-6812	.	_

Text=In addition, the model included covariates of no interest to account for the effect of 6 motion parameters (x, y, z, translation and roll, yaw and pitch).
43-1	6813-6815	In	_
43-2	6816-6824	addition	_
43-3	6825-6826	,	_
43-4	6827-6830	the	_
43-5	6831-6836	model	_
43-6	6837-6845	included	_
43-7	6846-6856	covariates	_
43-8	6857-6859	of	_
43-9	6860-6862	no	_
43-10	6863-6871	interest	_
43-11	6872-6874	to	_
43-12	6875-6882	account	_
43-13	6883-6886	for	_
43-14	6887-6890	the	_
43-15	6891-6897	effect	_
43-16	6898-6900	of	_
43-17	6901-6902	6	_
43-18	6903-6909	motion	_
43-19	6910-6920	parameters	_
43-20	6921-6922	(	_
43-21	6923-6924	x	_
43-22	6925-6926	,	_
43-23	6927-6928	y	_
43-24	6929-6930	,	_
43-25	6931-6932	z	_
43-26	6933-6934	,	_
43-27	6935-6946	translation	_
43-28	6947-6950	and	_
43-29	6951-6955	roll	_
43-30	6956-6957	,	_
43-31	6958-6961	yaw	_
43-32	6962-6965	and	_
43-33	6966-6971	pitch	_
43-34	6972-6973	)	_
43-35	6974-6975	.	_

Text=Vocal artifacts are limited to the first couple of seconds of responding and has limited effect on later hemodynamic response.
44-1	6976-6981	Vocal	_
44-2	6982-6991	artifacts	_
44-3	6992-6995	are	_
44-4	6996-7003	limited	_
44-5	7004-7006	to	_
44-6	7007-7010	the	_
44-7	7011-7016	first	_
44-8	7017-7023	couple	_
44-9	7024-7026	of	_
44-10	7027-7034	seconds	_
44-11	7035-7037	of	_
44-12	7038-7048	responding	_
44-13	7049-7052	and	_
44-14	7053-7056	has	_
44-15	7057-7064	limited	_
44-16	7065-7071	effect	_
44-17	7072-7074	on	_
44-18	7075-7080	later	_
44-19	7081-7092	hemodynamic	_
44-20	7093-7101	response	_
44-21	7102-7103	.	_

Text=For each individual, estimated parameters of the regressors (beta weights) were calculated for each voxel using the GLM and were used in t-tests to assess the main effect of correct Dual> Single trials.
45-1	7104-7107	For	_
45-2	7108-7112	each	_
45-3	7113-7123	individual	_
45-4	7124-7125	,	_
45-5	7126-7135	estimated	_
45-6	7136-7146	parameters	_
45-7	7147-7149	of	_
45-8	7150-7153	the	_
45-9	7154-7164	regressors	_
45-10	7165-7166	(	_
45-11	7167-7171	beta	_
45-12	7172-7179	weights	_
45-13	7180-7181	)	_
45-14	7182-7186	were	_
45-15	7187-7197	calculated	_
45-16	7198-7201	for	_
45-17	7202-7206	each	_
45-18	7207-7212	voxel	_
45-19	7213-7218	using	_
45-20	7219-7222	the	_
45-21	7223-7226	GLM	_
45-22	7227-7230	and	_
45-23	7231-7235	were	_
45-24	7236-7240	used	_
45-25	7241-7243	in	_
45-26	7244-7251	t-tests	_
45-27	7252-7254	to	_
45-28	7255-7261	assess	_
45-29	7262-7265	the	_
45-30	7266-7270	main	_
45-31	7271-7277	effect	_
45-32	7278-7280	of	_
45-33	7281-7288	correct	_
45-34	7289-7293	Dual	_
45-35	7294-7295	>	_
45-36	7296-7302	Single	_
45-37	7303-7309	trials	_
45-38	7310-7311	.	_

Text=Within group analyses were conducted separately for healthy and schizophrenia groups using subject level Dual> Single contrast images.
46-1	7312-7318	Within	_
46-2	7319-7324	group	_
46-3	7325-7333	analyses	_
46-4	7334-7338	were	_
46-5	7339-7348	conducted	_
46-6	7349-7359	separately	_
46-7	7360-7363	for	_
46-8	7364-7371	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
46-9	7372-7375	and	_
46-10	7376-7389	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
46-11	7390-7396	groups	_
46-12	7397-7402	using	_
46-13	7403-7410	subject	_
46-14	7411-7416	level	_
46-15	7417-7421	Dual	_
46-16	7422-7423	>	_
46-17	7424-7430	Single	_
46-18	7431-7439	contrast	_
46-19	7440-7446	images	_
46-20	7447-7448	.	_

Text=Between group analyses were investigated for the Dual> Single contrast images from each individual using subject as a random effect.
47-1	7449-7456	Between	_
47-2	7457-7462	group	_
47-3	7463-7471	analyses	_
47-4	7472-7476	were	_
47-5	7477-7489	investigated	_
47-6	7490-7493	for	_
47-7	7494-7497	the	_
47-8	7498-7502	Dual	_
47-9	7503-7504	>	_
47-10	7505-7511	Single	_
47-11	7512-7520	contrast	_
47-12	7521-7527	images	_
47-13	7528-7532	from	_
47-14	7533-7537	each	_
47-15	7538-7548	individual	_
47-16	7549-7554	using	_
47-17	7555-7562	subject	_
47-18	7563-7565	as	_
47-19	7566-7567	a	_
47-20	7568-7574	random	_
47-21	7575-7581	effect	_
47-22	7582-7583	.	_

Text=This analysis identifies regions that show a condition by group interaction.
48-1	7584-7588	This	_
48-2	7589-7597	analysis	_
48-3	7598-7608	identifies	_
48-4	7609-7616	regions	_
48-5	7617-7621	that	_
48-6	7622-7626	show	_
48-7	7627-7628	a	_
48-8	7629-7638	condition	_
48-9	7639-7641	by	_
48-10	7642-7647	group	_
48-11	7648-7659	interaction	_
48-12	7660-7661	.	_

Text=As we were interested in how the two groups differ in task relevant brain regions, whole brain group comparisons were masked for the Dual> Single contrast, collapsed across all subjects (thresholded at p <0.05, uncorrected).
49-1	7662-7664	As	_
49-2	7665-7667	we	_
49-3	7668-7672	were	_
49-4	7673-7683	interested	_
49-5	7684-7686	in	_
49-6	7687-7690	how	_
49-7	7691-7694	the	_
49-8	7695-7698	two	_
49-9	7699-7705	groups	_
49-10	7706-7712	differ	_
49-11	7713-7715	in	_
49-12	7716-7720	task	_
49-13	7721-7729	relevant	_
49-14	7730-7735	brain	_
49-15	7736-7743	regions	_
49-16	7744-7745	,	_
49-17	7746-7751	whole	_
49-18	7752-7757	brain	_
49-19	7758-7763	group	_
49-20	7764-7775	comparisons	_
49-21	7776-7780	were	_
49-22	7781-7787	masked	_
49-23	7788-7791	for	_
49-24	7792-7795	the	_
49-25	7796-7800	Dual	_
49-26	7801-7802	>	_
49-27	7803-7809	Single	_
49-28	7810-7818	contrast	_
49-29	7819-7820	,	_
49-30	7821-7830	collapsed	_
49-31	7831-7837	across	_
49-32	7838-7841	all	_
49-33	7842-7850	subjects	_
49-34	7851-7852	(	_
49-35	7853-7864	thresholded	_
49-36	7865-7867	at	_
49-37	7868-7869	p	_
49-38	7870-7871	<	_
49-39	7872-7876	0.05	_
49-40	7877-7878	,	_
49-41	7879-7890	uncorrected	_
49-42	7891-7892	)	_
49-43	7893-7894	.	_

Text=For all masked analyses, we used small volume correction (SVC) to define cluster level significance.
50-1	7895-7898	For	_
50-2	7899-7902	all	_
50-3	7903-7909	masked	_
50-4	7910-7918	analyses	_
50-5	7919-7920	,	_
50-6	7921-7923	we	_
50-7	7924-7928	used	_
50-8	7929-7934	small	_
50-9	7935-7941	volume	_
50-10	7942-7952	correction	_
50-11	7953-7954	(	_
50-12	7955-7958	SVC	_
50-13	7959-7960	)	_
50-14	7961-7963	to	_
50-15	7964-7970	define	_
50-16	7971-7978	cluster	_
50-17	7979-7984	level	_
50-18	7985-7997	significance	_
50-19	7998-7999	.	_

Text=All contrasts used a voxel wise threshold of p <0.005 to detect cluster level significance.
51-1	8000-8003	All	_
51-2	8004-8013	contrasts	_
51-3	8014-8018	used	_
51-4	8019-8020	a	_
51-5	8021-8026	voxel	_
51-6	8027-8031	wise	_
51-7	8032-8041	threshold	_
51-8	8042-8044	of	_
51-9	8045-8046	p	_
51-10	8047-8048	<	_
51-11	8049-8054	0.005	_
51-12	8055-8057	to	_
51-13	8058-8064	detect	_
51-14	8065-8072	cluster	_
51-15	8073-8078	level	_
51-16	8079-8091	significance	_
51-17	8092-8093	.	_

Text=Region-of-Interest Analysis: PFC and Thalamus To further investigate PFC activation and thalamus-PFC connectivity, we defined 4 PFC regions of interest (ROIs) based on task activations.
52-1	8094-8112	Region-of-Interest	_
52-2	8113-8121	Analysis	_
52-3	8122-8123	:	_
52-4	8124-8127	PFC	_
52-5	8128-8131	and	_
52-6	8132-8140	Thalamus	_
52-7	8141-8143	To	_
52-8	8144-8151	further	_
52-9	8152-8163	investigate	_
52-10	8164-8167	PFC	_
52-11	8168-8178	activation	_
52-12	8179-8182	and	_
52-13	8183-8195	thalamus-PFC	_
52-14	8196-8208	connectivity	_
52-15	8209-8210	,	_
52-16	8211-8213	we	_
52-17	8214-8221	defined	_
52-18	8222-8223	4	_
52-19	8224-8227	PFC	_
52-20	8228-8235	regions	_
52-21	8236-8238	of	_
52-22	8239-8247	interest	_
52-23	8248-8249	(	_
52-24	8250-8254	ROIs	_
52-25	8255-8256	)	_
52-26	8257-8262	based	_
52-27	8263-8265	on	_
52-28	8266-8270	task	_
52-29	8271-8282	activations	_
52-30	8283-8284	.	_

Text=First, a prefrontal cortex mask was created using the frontal pole, superior frontal gyrus, middle frontal gyrus, inferior frontal gyrus pars triangularis and pars opercularis ROIs from the Harvard-Oxford cortical atlas (; https: //fsl.fmrib.ox.ac.uk/fsl/fslwiki/Atlases).
53-1	8285-8290	First	_
53-2	8291-8292	,	_
53-3	8293-8294	a	_
53-4	8295-8305	prefrontal	_
53-5	8306-8312	cortex	_
53-6	8313-8317	mask	_
53-7	8318-8321	was	_
53-8	8322-8329	created	_
53-9	8330-8335	using	_
53-10	8336-8339	the	_
53-11	8340-8347	frontal	_
53-12	8348-8352	pole	_
53-13	8353-8354	,	_
53-14	8355-8363	superior	_
53-15	8364-8371	frontal	_
53-16	8372-8377	gyrus	_
53-17	8378-8379	,	_
53-18	8380-8386	middle	_
53-19	8387-8394	frontal	_
53-20	8395-8400	gyrus	_
53-21	8401-8402	,	_
53-22	8403-8411	inferior	_
53-23	8412-8419	frontal	_
53-24	8420-8425	gyrus	_
53-25	8426-8430	pars	_
53-26	8431-8443	triangularis	_
53-27	8444-8447	and	_
53-28	8448-8452	pars	_
53-29	8453-8464	opercularis	_
53-30	8465-8469	ROIs	_
53-31	8470-8474	from	_
53-32	8475-8478	the	_
53-33	8479-8493	Harvard-Oxford	_
53-34	8494-8502	cortical	_
53-35	8503-8508	atlas	_
53-36	8509-8510	(	_
53-37	8511-8512	;	_
53-38	8513-8518	https	_
53-39	8519-8520	:	_
53-40	8521-8561	//fsl.fmrib.ox.ac.uk/fsl/fslwiki/Atlases	_
53-41	8562-8563	)	_
53-42	8564-8565	.	_

Text=All significant clusters in the Dual> Single contrast (collapsed across all subjects, p <0.05, FDRSVC) falling within this PFC mask were extracted.
54-1	8566-8569	All	_
54-2	8570-8581	significant	_
54-3	8582-8590	clusters	_
54-4	8591-8593	in	_
54-5	8594-8597	the	_
54-6	8598-8602	Dual	_
54-7	8603-8604	>	_
54-8	8605-8611	Single	_
54-9	8612-8620	contrast	_
54-10	8621-8622	(	_
54-11	8623-8632	collapsed	_
54-12	8633-8639	across	_
54-13	8640-8643	all	_
54-14	8644-8652	subjects	_
54-15	8653-8654	,	_
54-16	8655-8656	p	_
54-17	8657-8658	<	_
54-18	8659-8663	0.05	_
54-19	8664-8665	,	_
54-20	8666-8672	FDRSVC	_
54-21	8673-8674	)	_
54-22	8675-8682	falling	_
54-23	8683-8689	within	_
54-24	8690-8694	this	_
54-25	8695-8698	PFC	_
54-26	8699-8703	mask	_
54-27	8704-8708	were	_
54-28	8709-8718	extracted	_
54-29	8719-8720	.	_

Text=A total of 4 ROIs were defined this way.
55-1	8721-8722	A	_
55-2	8723-8728	total	_
55-3	8729-8731	of	_
55-4	8732-8733	4	_
55-5	8734-8738	ROIs	_
55-6	8739-8743	were	_
55-7	8744-8751	defined	_
55-8	8752-8756	this	_
55-9	8757-8760	way	_
55-10	8761-8762	.	_

Text=They included the midline (pre) supplementary motor area (pre-SMA/SMA; −4, 10, 56; 357 voxels), left frontal eye fields (FEF; −32, 0, 52; 367 voxels), right lateral PFC (LPFC; 42, 10, 24; 402 voxels) and the left LPFC (40, 15, 22; 97 voxels).
56-1	8763-8767	They	_
56-2	8768-8776	included	_
56-3	8777-8780	the	_
56-4	8781-8788	midline	_
56-5	8789-8790	(	_
56-6	8791-8794	pre	_
56-7	8795-8796	)	_
56-8	8797-8810	supplementary	_
56-9	8811-8816	motor	_
56-10	8817-8821	area	_
56-11	8822-8823	(	_
56-12	8824-8835	pre-SMA/SMA	_
56-13	8836-8837	;	_
56-14	8838-8840	−4	_
56-15	8841-8842	,	_
56-16	8843-8845	10	_
56-17	8846-8847	,	_
56-18	8848-8850	56	_
56-19	8851-8852	;	_
56-20	8853-8856	357	_
56-21	8857-8863	voxels	_
56-22	8864-8865	)	_
56-23	8866-8867	,	_
56-24	8868-8872	left	_
56-25	8873-8880	frontal	_
56-26	8881-8884	eye	_
56-27	8885-8891	fields	_
56-28	8892-8893	(	_
56-29	8894-8897	FEF	_
56-30	8898-8899	;	_
56-31	8900-8903	−32	_
56-32	8904-8905	,	_
56-33	8906-8907	0	_
56-34	8908-8909	,	_
56-35	8910-8912	52	_
56-36	8913-8914	;	_
56-37	8915-8918	367	_
56-38	8919-8925	voxels	_
56-39	8926-8927	)	_
56-40	8928-8929	,	_
56-41	8930-8935	right	_
56-42	8936-8943	lateral	_
56-43	8944-8947	PFC	_
56-44	8948-8949	(	_
56-45	8950-8954	LPFC	_
56-46	8955-8956	;	_
56-47	8957-8959	42	_
56-48	8960-8961	,	_
56-49	8962-8964	10	_
56-50	8965-8966	,	_
56-51	8967-8969	24	_
56-52	8970-8971	;	_
56-53	8972-8975	402	_
56-54	8976-8982	voxels	_
56-55	8983-8984	)	_
56-56	8985-8988	and	_
56-57	8989-8992	the	_
56-58	8993-8997	left	_
56-59	8998-9002	LPFC	_
56-60	9003-9004	(	_
56-61	9005-9007	40	_
56-62	9008-9009	,	_
56-63	9010-9012	15	_
56-64	9013-9014	,	_
56-65	9015-9017	22	_
56-66	9018-9019	;	_
56-67	9020-9022	97	_
56-68	9023-9029	voxels	_
56-69	9030-9031	)	_
56-70	9032-9033	.	_

Text=For the all PFC ROI analyses, reported p-values were adjusted for Bonferroni corrected values based on 4 tests conducted.
57-1	9034-9037	For	_
57-2	9038-9041	the	_
57-3	9042-9045	all	_
57-4	9046-9049	PFC	_
57-5	9050-9053	ROI	_
57-6	9054-9062	analyses	_
57-7	9063-9064	,	_
57-8	9065-9073	reported	_
57-9	9074-9082	p-values	_
57-10	9083-9087	were	_
57-11	9088-9096	adjusted	_
57-12	9097-9100	for	_
57-13	9101-9111	Bonferroni	_
57-14	9112-9121	corrected	_
57-15	9122-9128	values	_
57-16	9129-9134	based	_
57-17	9135-9137	on	_
57-18	9138-9139	4	_
57-19	9140-9145	tests	_
57-20	9146-9155	conducted	_
57-21	9156-9157	.	_

Text=For the thalamus, the voxel-wise between groups analysis was masked with a bilateral thalamus mask composed of the left and right thalamus from the Harvard-Oxford atlas.
58-1	9158-9161	For	_
58-2	9162-9165	the	_
58-3	9166-9174	thalamus	_
58-4	9175-9176	,	_
58-5	9177-9180	the	_
58-6	9181-9191	voxel-wise	_
58-7	9192-9199	between	_
58-8	9200-9206	groups	_
58-9	9207-9215	analysis	_
58-10	9216-9219	was	_
58-11	9220-9226	masked	_
58-12	9227-9231	with	_
58-13	9232-9233	a	_
58-14	9234-9243	bilateral	_
58-15	9244-9252	thalamus	_
58-16	9253-9257	mask	_
58-17	9258-9266	composed	_
58-18	9267-9269	of	_
58-19	9270-9273	the	_
58-20	9274-9278	left	_
58-21	9279-9282	and	_
58-22	9283-9288	right	_
58-23	9289-9297	thalamus	_
58-24	9298-9302	from	_
58-25	9303-9306	the	_
58-26	9307-9321	Harvard-Oxford	_
58-27	9322-9327	atlas	_
58-28	9328-9329	.	_

Text=To further investigate activation patterns across different thalamic regions, we used the Morel atlas to define 3 thalamic regions covering the mediodorsal nucleus (MD; 236 voxels), the pulvinar (PUL; 543 voxels) and the ventrolateral nucleus (VL; 361 voxels).
59-1	9330-9332	To	_
59-2	9333-9340	further	_
59-3	9341-9352	investigate	_
59-4	9353-9363	activation	_
59-5	9364-9372	patterns	_
59-6	9373-9379	across	_
59-7	9380-9389	different	_
59-8	9390-9398	thalamic	_
59-9	9399-9406	regions	_
59-10	9407-9408	,	_
59-11	9409-9411	we	_
59-12	9412-9416	used	_
59-13	9417-9420	the	_
59-14	9421-9426	Morel	_
59-15	9427-9432	atlas	_
59-16	9433-9435	to	_
59-17	9436-9442	define	_
59-18	9443-9444	3	_
59-19	9445-9453	thalamic	_
59-20	9454-9461	regions	_
59-21	9462-9470	covering	_
59-22	9471-9474	the	_
59-23	9475-9486	mediodorsal	_
59-24	9487-9494	nucleus	_
59-25	9495-9496	(	_
59-26	9497-9499	MD	_
59-27	9500-9501	;	_
59-28	9502-9505	236	_
59-29	9506-9512	voxels	_
59-30	9513-9514	)	_
59-31	9515-9516	,	_
59-32	9517-9520	the	_
59-33	9521-9529	pulvinar	_
59-34	9530-9531	(	_
59-35	9532-9535	PUL	_
59-36	9536-9537	;	_
59-37	9538-9541	543	_
59-38	9542-9548	voxels	_
59-39	9549-9550	)	_
59-40	9551-9554	and	_
59-41	9555-9558	the	_
59-42	9559-9572	ventrolateral	_
59-43	9573-9580	nucleus	_
59-44	9581-9582	(	_
59-45	9583-9585	VL	_
59-46	9586-9587	;	_
59-47	9588-9591	361	_
59-48	9592-9598	voxels	_
59-49	9599-9600	)	_
59-50	9601-9602	.	_

Text=These 4 thalamus ROIs are presented in Supplementary Figure 1.
60-1	9603-9608	These	_
60-2	9609-9610	4	_
60-3	9611-9619	thalamus	_
60-4	9620-9624	ROIs	_
60-5	9625-9628	are	_
60-6	9629-9638	presented	_
60-7	9639-9641	in	_
60-8	9642-9655	Supplementary	_
60-9	9656-9662	Figure	_
60-10	9663-9664	1	_
60-11	9665-9666	.	_

Text=To correct for multiple thalamic regions, we report Bonferroni corrected p-values based on 3 tests conducted.
61-1	9667-9669	To	_
61-2	9670-9677	correct	_
61-3	9678-9681	for	_
61-4	9682-9690	multiple	_
61-5	9691-9699	thalamic	_
61-6	9700-9707	regions	_
61-7	9708-9709	,	_
61-8	9710-9712	we	_
61-9	9713-9719	report	_
61-10	9720-9730	Bonferroni	_
61-11	9731-9740	corrected	_
61-12	9741-9749	p-values	_
61-13	9750-9755	based	_
61-14	9756-9758	on	_
61-15	9759-9760	3	_
61-16	9761-9766	tests	_
61-17	9767-9776	conducted	_
61-18	9777-9778	.	_

Text=To ensure that these effects were not driven by differences in performance, a secondary set of analyses including only high performing subjects was also conducted (see Supplementary Table 3).
62-1	9779-9781	To	_
62-2	9782-9788	ensure	_
62-3	9789-9793	that	_
62-4	9794-9799	these	_
62-5	9800-9807	effects	_
62-6	9808-9812	were	_
62-7	9813-9816	not	_
62-8	9817-9823	driven	_
62-9	9824-9826	by	_
62-10	9827-9838	differences	_
62-11	9839-9841	in	_
62-12	9842-9853	performance	_
62-13	9854-9855	,	_
62-14	9856-9857	a	_
62-15	9858-9867	secondary	_
62-16	9868-9871	set	_
62-17	9872-9874	of	_
62-18	9875-9883	analyses	_
62-19	9884-9893	including	_
62-20	9894-9898	only	_
62-21	9899-9903	high	_
62-22	9904-9914	performing	_
62-23	9915-9923	subjects	_
62-24	9924-9927	was	_
62-25	9928-9932	also	_
62-26	9933-9942	conducted	_
62-27	9943-9944	(	_
62-28	9945-9948	see	_
62-29	9949-9962	Supplementary	_
62-30	9963-9968	Table	_
62-31	9969-9970	3	_
62-32	9971-9972	)	_
62-33	9973-9974	.	_

Text=Beta-series Connectivity Task connectivity was conducted using the beta-series correlation analysis method.
63-1	9975-9986	Beta-series	_
63-2	9987-9999	Connectivity	_
63-3	10000-10004	Task	_
63-4	10005-10017	connectivity	_
63-5	10018-10021	was	_
63-6	10022-10031	conducted	_
63-7	10032-10037	using	_
63-8	10038-10041	the	_
63-9	10042-10053	beta-series	_
63-10	10054-10065	correlation	_
63-11	10066-10074	analysis	_
63-12	10075-10081	method	_
63-13	10082-10083	.	_

Text=Beta-series connectivity refers to a method of examining task connectivity by isolating a brain region ’ s response to an event in a task (e.g.
64-1	10084-10095	Beta-series	_
64-2	10096-10108	connectivity	_
64-3	10109-10115	refers	_
64-4	10116-10118	to	_
64-5	10119-10120	a	_
64-6	10121-10127	method	_
64-7	10128-10130	of	_
64-8	10131-10140	examining	_
64-9	10141-10145	task	_
64-10	10146-10158	connectivity	_
64-11	10159-10161	by	_
64-12	10162-10171	isolating	_
64-13	10172-10173	a	_
64-14	10174-10179	brain	_
64-15	10180-10186	region	_
64-16	10187-10188	’	_
64-17	10189-10190	s	_
64-18	10191-10199	response	_
64-19	10200-10202	to	_
64-20	10203-10205	an	_
64-21	10206-10211	event	_
64-22	10212-10214	in	_
64-23	10215-10216	a	_
64-24	10217-10221	task	_
64-25	10222-10223	(	_
64-26	10224-10227	e.g	_
64-27	10228-10229	.	_

Text=cue presentation) and then characterizing the covariance between task response in other brain regions, separately for each condition of interest.
65-1	10230-10233	cue	_
65-2	10234-10246	presentation	_
65-3	10247-10248	)	_
65-4	10249-10252	and	_
65-5	10253-10257	then	_
65-6	10258-10272	characterizing	_
65-7	10273-10276	the	_
65-8	10277-10287	covariance	_
65-9	10288-10295	between	_
65-10	10296-10300	task	_
65-11	10301-10309	response	_
65-12	10310-10312	in	_
65-13	10313-10318	other	_
65-14	10319-10324	brain	_
65-15	10325-10332	regions	_
65-16	10333-10334	,	_
65-17	10335-10345	separately	_
65-18	10346-10349	for	_
65-19	10350-10354	each	_
65-20	10355-10364	condition	_
65-21	10365-10367	of	_
65-22	10368-10376	interest	_
65-23	10377-10378	.	_

Text=Beta-series differs from the more conventional psychophysiological interactions (PPI) method for investigating task connectivity in that power is derived from the number of trials/events presented, rather than based on time course correlations.
66-1	10379-10390	Beta-series	_
66-2	10391-10398	differs	_
66-3	10399-10403	from	_
66-4	10404-10407	the	_
66-5	10408-10412	more	_
66-6	10413-10425	conventional	_
66-7	10426-10445	psychophysiological	_
66-8	10446-10458	interactions	_
66-9	10459-10460	(	_
66-10	10461-10464	PPI	_
66-11	10465-10466	)	_
66-12	10467-10473	method	_
66-13	10474-10477	for	_
66-14	10478-10491	investigating	_
66-15	10492-10496	task	_
66-16	10497-10509	connectivity	_
66-17	10510-10512	in	_
66-18	10513-10517	that	_
66-19	10518-10523	power	_
66-20	10524-10526	is	_
66-21	10527-10534	derived	_
66-22	10535-10539	from	_
66-23	10540-10543	the	_
66-24	10544-10550	number	_
66-25	10551-10553	of	_
66-26	10554-10567	trials/events	_
66-27	10568-10577	presented	_
66-28	10578-10579	,	_
66-29	10580-10586	rather	_
66-30	10587-10591	than	_
66-31	10592-10597	based	_
66-32	10598-10600	on	_
66-33	10601-10605	time	_
66-34	10606-10612	course	_
66-35	10613-10625	correlations	_
66-36	10626-10627	.	_

Text=In designs with many trials (> 30) and short events, beta-series provides superior power to detect connectivity than PPI.
67-1	10628-10630	In	_
67-2	10631-10638	designs	_
67-3	10639-10643	with	_
67-4	10644-10648	many	_
67-5	10649-10655	trials	_
67-6	10656-10657	(	_
67-7	10658-10659	>	_
67-8	10660-10662	30	_
67-9	10663-10664	)	_
67-10	10665-10668	and	_
67-11	10669-10674	short	_
67-12	10675-10681	events	_
67-13	10682-10683	,	_
67-14	10684-10695	beta-series	_
67-15	10696-10704	provides	_
67-16	10705-10713	superior	_
67-17	10714-10719	power	_
67-18	10720-10722	to	_
67-19	10723-10729	detect	_
67-20	10730-10742	connectivity	_
67-21	10743-10747	than	_
67-22	10748-10751	PPI	_
67-23	10752-10753	.	_

Text=We constructed a GLM model including a regressor per trial to compute a separate parameter estimate (beta value) for each trial, resulting in 120 covariates of interest entered into the GLM (60 Single and 60 Dual trials).
68-1	10754-10756	We	_
68-2	10757-10768	constructed	_
68-3	10769-10770	a	_
68-4	10771-10774	GLM	_
68-5	10775-10780	model	_
68-6	10781-10790	including	_
68-7	10791-10792	a	_
68-8	10793-10802	regressor	_
68-9	10803-10806	per	_
68-10	10807-10812	trial	_
68-11	10813-10815	to	_
68-12	10816-10823	compute	_
68-13	10824-10825	a	_
68-14	10826-10834	separate	_
68-15	10835-10844	parameter	_
68-16	10845-10853	estimate	_
68-17	10854-10855	(	_
68-18	10856-10860	beta	_
68-19	10861-10866	value	_
68-20	10867-10868	)	_
68-21	10869-10872	for	_
68-22	10873-10877	each	_
68-23	10878-10883	trial	_
68-24	10884-10885	,	_
68-25	10886-10895	resulting	_
68-26	10896-10898	in	_
68-27	10899-10902	120	_
68-28	10903-10913	covariates	_
68-29	10914-10916	of	_
68-30	10917-10925	interest	_
68-31	10926-10933	entered	_
68-32	10934-10938	into	_
68-33	10939-10942	the	_
68-34	10943-10946	GLM	_
68-35	10947-10948	(	_
68-36	10949-10951	60	_
68-37	10952-10958	Single	_
68-38	10959-10962	and	_
68-39	10963-10965	60	_
68-40	10966-10970	Dual	_
68-41	10971-10977	trials	_
68-42	10978-10979	)	_
68-43	10980-10981	.	_

Text=The GLM also included covariates of no interest to model the effects of shifting signal levels across runs and 6 motion parameters.
69-1	10982-10985	The	_
69-2	10986-10989	GLM	_
69-3	10990-10994	also	_
69-4	10995-11003	included	_
69-5	11004-11014	covariates	_
69-6	11015-11017	of	_
69-7	11018-11020	no	_
69-8	11021-11029	interest	_
69-9	11030-11032	to	_
69-10	11033-11038	model	_
69-11	11039-11042	the	_
69-12	11043-11050	effects	_
69-13	11051-11053	of	_
69-14	11054-11062	shifting	_
69-15	11063-11069	signal	_
69-16	11070-11076	levels	_
69-17	11077-11083	across	_
69-18	11084-11088	runs	_
69-19	11089-11092	and	_
69-20	11093-11094	6	_
69-21	11095-11101	motion	_
69-22	11102-11112	parameters	_
69-23	11113-11114	.	_

Text=This GLM resulted in a unique set of 120 beta values for each voxel in the brain.
70-1	11115-11119	This	_
70-2	11120-11123	GLM	_
70-3	11124-11132	resulted	_
70-4	11133-11135	in	_
70-5	11136-11137	a	_
70-6	11138-11144	unique	_
70-7	11145-11148	set	_
70-8	11149-11151	of	_
70-9	11152-11155	120	_
70-10	11156-11160	beta	_
70-11	11161-11167	values	_
70-12	11168-11171	for	_
70-13	11172-11176	each	_
70-14	11177-11182	voxel	_
70-15	11183-11185	in	_
70-16	11186-11189	the	_
70-17	11190-11195	brain	_
70-18	11196-11197	.	_

Text=Beta values from correct trials were sorted into Single and Dual ‘ beta series ’ for each voxel in the brain.
71-1	11198-11202	Beta	_
71-2	11203-11209	values	_
71-3	11210-11214	from	_
71-4	11215-11222	correct	_
71-5	11223-11229	trials	_
71-6	11230-11234	were	_
71-7	11235-11241	sorted	_
71-8	11242-11246	into	_
71-9	11247-11253	Single	_
71-10	11254-11257	and	_
71-11	11258-11262	Dual	_
71-12	11263-11264	‘	_
71-13	11265-11269	beta	_
71-14	11270-11276	series	_
71-15	11277-11278	’	_
71-16	11279-11282	for	_
71-17	11283-11287	each	_
71-18	11288-11293	voxel	_
71-19	11294-11296	in	_
71-20	11297-11300	the	_
71-21	11301-11306	brain	_
71-22	11307-11308	.	_

Text=The task-based thalamus region from the between groups comparison of the Dual> Single contrast was used as a seed.
72-1	11309-11312	The	_
72-2	11313-11323	task-based	_
72-3	11324-11332	thalamus	_
72-4	11333-11339	region	_
72-5	11340-11344	from	_
72-6	11345-11348	the	_
72-7	11349-11356	between	_
72-8	11357-11363	groups	_
72-9	11364-11374	comparison	_
72-10	11375-11377	of	_
72-11	11378-11381	the	_
72-12	11382-11386	Dual	_
72-13	11387-11388	>	_
72-14	11389-11395	Single	_
72-15	11396-11404	contrast	_
72-16	11405-11408	was	_
72-17	11409-11413	used	_
72-18	11414-11416	as	_
72-19	11417-11418	a	_
72-20	11419-11423	seed	_
72-21	11424-11425	.	_

Text=Connectivity between this thalamus seed and each PFC ROI was calculated for the Dual and Single conditions by correlating their respective beta series.
73-1	11426-11438	Connectivity	_
73-2	11439-11446	between	_
73-3	11447-11451	this	_
73-4	11452-11460	thalamus	_
73-5	11461-11465	seed	_
73-6	11466-11469	and	_
73-7	11470-11474	each	_
73-8	11475-11478	PFC	_
73-9	11479-11482	ROI	_
73-10	11483-11486	was	_
73-11	11487-11497	calculated	_
73-12	11498-11501	for	_
73-13	11502-11505	the	_
73-14	11506-11510	Dual	_
73-15	11511-11514	and	_
73-16	11515-11521	Single	_
73-17	11522-11532	conditions	_
73-18	11533-11535	by	_
73-19	11536-11547	correlating	_
73-20	11548-11553	their	_
73-21	11554-11564	respective	_
73-22	11565-11569	beta	_
73-23	11570-11576	series	_
73-24	11577-11578	.	_

Text=Additional analyses examining beta series connectivity from the MD, PUL and VL to the left LPFC are included in Supplementary Figure 2.
74-1	11579-11589	Additional	_
74-2	11590-11598	analyses	_
74-3	11599-11608	examining	_
74-4	11609-11613	beta	_
74-5	11614-11620	series	_
74-6	11621-11633	connectivity	_
74-7	11634-11638	from	_
74-8	11639-11642	the	_
74-9	11643-11645	MD	_
74-10	11646-11647	,	_
74-11	11648-11651	PUL	_
74-12	11652-11655	and	_
74-13	11656-11658	VL	_
74-14	11659-11661	to	_
74-15	11662-11665	the	_
74-16	11666-11670	left	_
74-17	11671-11675	LPFC	_
74-18	11676-11679	are	_
74-19	11680-11688	included	_
74-20	11689-11691	in	_
74-21	11692-11705	Supplementary	_
74-22	11706-11712	Figure	_
74-23	11713-11714	2	_
74-24	11715-11716	.	_

